High-activity blood coagulation factor XI mutant Ala570Thr
AssigneesRuijin Hospital Shanghai Jiaotong University School of Medicine, Wenman Wu, Xuefeng Wang, Qiulan Ding
InventorsWenman Wu, Xuefeng Wang, Qiulan Ding
Life of this patent
Estimating the term…
Abstract
A high-activity blood coagulation factor XI mutant Ala570Thr (A570T), having nucleotide sequences as shown in SEQ ID NOs: 1-4 and an amino acid sequence as shown in SEQ ID NO: 5, is provided. The mutant is resistant to a physiological inhibitor thereof after being activated from a zymogen state to an active enzyme. Therefore, the mutant has a very high blood coagulation activity and a stronger catalytic ability for a non-physiological substrate; and the mutant is applied to the treatment of hemorrhagic diseases, and has good prospects in terms of gene therapy, gene editing and recombinant protein replacement treatments.
Claims5
A blood coagulation factor XI mutant Ala570Thr nucleic acid sequence, having:
- (a) the nucleotide sequence as shown in SEQ ID NO:
- 1;
- or
- (b) the nucleotide sequence as shown in SEQ ID NO:
- 2;
- or
- (c) the nucleotide sequence as shown in SEQ ID NO:
- 3;
- or
- (d) the nucleotide sequence as shown in SEQ ID NO:
- 4.
A blood coagulation factor XI mutant Ala570Thr, comprising the amino acid sequence of SEQ ID NO:
- 5, and an amino acid located at position 570 of the mutant is Thr rather than Ala of non-human wild-type factor XI.
Dependencies are inferred from the claim text.